source
- Beeline Medicines reports promising Phase 2 lupus dataBeeline Medicines, a Bain‑backed startup, announced encouraging mid‑stage results for its lupus candidate afimetoran, a drug originally sourced from Bristol Myers Squibb. The Phase 2 trial data we…
- Researchers urge FDA to adopt EMA-style drug rejection letter disclosuresThe FDA began publishing letters that explain why a drug application was denied in September 2025, marking a significant transparency shift. Researchers argue that the agency’s current disclosures…